1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Kidney Cancer - Pipeline Review, H2 2013

Kidney Cancer - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 159 pages

Kidney Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Kidney Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Kidney Cancer.
- A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Kidney Cancer - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Kidney Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Kidney Cancer 9
Kidney Cancer Therapeutics under Development by Companies 11
Kidney Cancer Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Kidney Cancer Therapeutics - Products under Development by Companies 19
Kidney Cancer Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Kidney Cancer Therapeutics Development 22
Amgen Inc. 22
Amorfix Life Sciences Ltd. 23
Astellas Pharma Inc. 24
Onyx Pharmaceuticals, Inc. 25
Patrys Limited 26
Dendreon Corporation 27
Green Cross Corporation 28
Rexahn Pharmaceuticals, Inc. 29
Antisense Pharma GmbH 30
Chipscreen Biosciences Ltd 31
CIMAB S.A. 32
Aurigene Discovery Technologies Limited 33
Alethia Biotherapeutics Inc. 34
GenSpera, Inc. 35
Cerulean Pharma, Inc. 36
Gene Signal International SA. 37
Neotropix, Inc. 38
Deciphera Pharmaceuticals, LLC 39
MSM Protein Technologies, Inc. 40
Vascular Biogenics Ltd. 41
Pharminox Limited 42
Esperance Pharmaceuticals, Inc. 43
Welichem Biotech Inc. 44
Cellceutix Corporation 45
TRACON Pharmaceuticals, Inc. 46
Advanced Cancer Therapeutics 47
RECEPTA Biopharma S.A. 48
Mediolanum farmaceutici S.p.A. 49
FCB-Pharmicell Co.,Ltd. 50
Kidney Cancer - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 57
trebananib - Drug Profile 57
OSI-930 - Drug Profile 60
NTX-010 - Drug Profile 61
Drug Targeting Carbonic Anhydrase IX - Drug Profile 63
carfilzomib - Drug Profile 64
PMX-2058 - Drug Profile 67
VB-111 - Drug Profile 68
trabedersen - Drug Profile 69
Kevetrin - Drug Profile 71
CRLX-101 - Drug Profile 74
WBI-2100 - Drug Profile 76
GS-168 - Drug Profile 77
G-202 - Drug Profile 78
RX-5902 - Drug Profile 80
CS-2164 - Drug Profile 81
Angiotensin 1-7 - Drug Profile 82
PU-27 - Drug Profile 83
EP-302 - Drug Profile 84
TRC-105 - Drug Profile 86
rebastinib tosylate - Drug Profile 89
PAT-SM3 - Drug Profile 91
ETD-5 - Drug Profile 92
PMX-290 - Drug Profile 93
MG-1102 - Drug Profile 94
MSM-222 - Drug Profile 95
ONS-2010 - Drug Profile 96
AMF-3d-19 - Drug Profile 97
ER Stress and Autophagy Program - Drug Profile 98
Autophagy Program - Drug Profile 99
Tumor Metabolism Program - Drug Profile 100
Tumor Metabolism Program TBN - Drug Profile 101
AB-3A4 - Drug Profile 102
interleukin-15 - Drug Profile 103
AUR-012 - Drug Profile 105
Antibody Drug Conjugates Program - Drug Profile 106
BION-003 - Drug Profile 107
Drug For Cancer - Drug Profile 108
EP-300 - Drug Profile 109
pTM-NRP1 - Drug Profile 110
SVX-1 Vaccine - Drug Profile 111
Halistatin-3 - Drug Profile 112
Immunocellgram For Cancer - Drug Profile 113
NSC-743380 - Drug Profile 114
Humanized Anti-VEGF Monoclonal Antibody - Drug Profile 115
Englerin A - Drug Profile 116
LW-7 - Drug Profile 117
SHetA-2 - Drug Profile 118
Kidney Cancer Therapeutics - Drug Profile Updates 119
Kidney Cancer Therapeutics - Discontinued Products 146
Kidney Cancer Therapeutics - Dormant Products 147
Kidney Cancer - Product Development Milestones 149
Featured News and Press Releases 149
Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 156



List of Tables

Number of Products Under Development for Kidney Cancer, H2 2013 12
Products under Development for Kidney Cancer - Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 18
Comparative Analysis by Mid Clinical Stage Development, H2 2013 19
Comparative Analysis by Early Clinical Stage Development, H2 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Development by Companies, H2 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2013 24
Amgen Inc., H2 2013 25
Amorfix Life Sciences Ltd., H2 2013 26
Astellas Pharma Inc., H2 2013 27
Onyx Pharmaceuticals, Inc., H2 2013 28
Patrys Limited, H2 2013 29
Dendreon Corporation, H2 2013 30
Green Cross Corporation, H2 2013 31
Rexahn Pharmaceuticals, Inc., H2 2013 32
Antisense Pharma GmbH, H2 2013 33
Chipscreen Biosciences Ltd, H2 2013 34
CIMAB S.A., H2 2013 35
Aurigene Discovery Technologies Limited, H2 2013 36
Alethia Biotherapeutics Inc., H2 2013 37
GenSpera, Inc., H2 2013 38
Cerulean Pharma, Inc., H2 2013 39
Gene Signal International SA., H2 2013 40
Neotropix, Inc., H2 2013 41
Deciphera Pharmaceuticals, LLC, H2 2013 42
MSM Protein Technologies, Inc., H2 2013 43
Vascular Biogenics Ltd., H2 2013 44
Pharminox Limited, H2 2013 45
Esperance Pharmaceuticals, Inc., H2 2013 46
Welichem Biotech Inc., H2 2013 47
Cellceutix Corporation, H2 2013 48
TRACON Pharmaceuticals, Inc., H2 2013 49
Advanced Cancer Therapeutics, H2 2013 50
RECEPTA Biopharma S.A., H2 2013 51
Mediolanum farmaceutici S.p.A., H2 2013 52
FCB-Pharmicell Co.,Ltd., H2 2013 53
Assessment by Monotherapy Products, H2 2013 54
Assessment by Stage and Route of Administration, H2 2013 56
Assessment by Stage and Molecule Type, H2 2013 59
Kidney Cancer Therapeutics - Drug Profile Updates 122
Kidney Cancer Therapeutics - Discontinued Products 149
Kidney Cancer Therapeutics - Dormant Products 150
Kidney Cancer Therapeutics - Dormant Products (Contd..1) 151



List of Figures

Number of Products under Development for Kidney Cancer, H2 2013 12
Products under Development for Kidney Cancer - Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Mid Clinical Stage Products, H2 2013 19
Early Clinical Stage Products, H2 2013 20
Discovery and Pre-Clinical Stage Products, H2 2013 21
Assessment by Monotherapy Products, H2 2013 54
Assessment by Route of Administration, H2 2013 55
Assessment by Stage and Route of Administration, H2 2013 56
Assessment by Molecule Type, H2 2013 57
Assessment by Stage and Molecule Type, H2 2013 58



Companies Mentioned

Amgen Inc.
Amorfix Life Sciences Ltd.
Astellas Pharma Inc.
Onyx Pharmaceuticals, Inc.
Patrys Limited
Dendreon Corporation
Green Cross Corporation
Rexahn Pharmaceuticals, Inc.
Antisense Pharma GmbH
Chipscreen Biosciences Ltd
CIMAB S.A.
Aurigene Discovery Technologies Limited
Alethia Biotherapeutics Inc.
GenSpera, Inc.
Cerulean Pharma, Inc.
Gene Signal International SA.
Neotropix, Inc.
Deciphera Pharmaceuticals, LLC
MSM Protein Technologies, Inc.
Vascular Biogenics Ltd.
Pharminox Limited
Esperance Pharmaceuticals, Inc.
Welichem Biotech Inc.
Cellceutix Corporation
TRACON Pharmaceuticals, Inc.
Advanced Cancer Therapeutics
RECEPTA Biopharma S.A.
Mediolanum farmaceutici S.p.A.
FCB-Pharmicell Co.,Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016’, provides in depth ...

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2016

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.